Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Judge

Showing results (101-110 of 110) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 110 results.
American Journal of Nephrology|May 7, 2026
Effects of Sacubitril/Valsartan vs Irbesartan on Urine Tubular Biomarkers in CKD: Findings from the UK HARP-III TrialMichelle A Goonasekera, Greco B Malijan, Rebecca J Sardell, et al.
The Lancet. Diabetes & Endocrinology|October 13, 2025
Effects of empagliflozin on conventional and exploratory acute and chronic kidney outcomes: an individual participant-level meta-analysisWilliam G Herrington, Zhaojing J Che, Rebecca Sardell, et al.
Eclinicalmedicine|July 21, 2025
Effects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trialJunwen Zhou, Claire Williams, Natalie Staplin, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|November 12, 2024
The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trialParminder K Judge, Katherine R Tuttle, Natalie Staplin, et al.
Clinical Journal of the American Society of Nephrology : CJASN|July 1, 2024
Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trialKaitlin J Mayne, Rebecca J Sardell, Natalie Staplin, et al.
Clinical Journal of the American Society of Nephrology : CJASN|April 3, 2025
Frailty, Multimorbidity, and Polypharmacy: Exploratory Analyses of the Effects of Empagliflozin from the EMPA-KIDNEY TrialKaitlin J Mayne, Rebecca J Sardell, Natalie Staplin, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|November 2, 2025
Effects of Empagliflozin on Urine Biomarkers in EMPA-KIDNEYGreco B Malijan, Rebecca J Sardell, Natalie Staplin, et al.
Journal of the American Society of Nephrology : JASN|December 12, 2023
Effects of Empagliflozin on Fluid Overload, Weight, and Blood Pressure in CKDKaitlin J Mayne, Natalie Staplin, David F Keane, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|December 13, 2025
Effects of Empagliflozin on Kidney and Cardiac Magnetic Resonance Imaging Measures in Patients With CKD: An EMPA-KIDNEY Mechanistic SubstudyDoreen Zhu, Parminder K Judge, Susan T Francis, et al.
Cardiovascular Diabetology|May 7, 2026
CVOT Summit Report 2025: advances along the cardiovascular-kidney-metabolic disease continuumOliver Schnell, Arnav Agarwal, Michel Azizi, et al.
Pageof 11

Showing results (101-110 of 110) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 110 results.
American Journal of Nephrology|May 7, 2026
Effects of Sacubitril/Valsartan vs Irbesartan on Urine Tubular Biomarkers in CKD: Findings from the UK HARP-III TrialMichelle A Goonasekera, Greco B Malijan, Rebecca J Sardell, et al.
The Lancet. Diabetes & Endocrinology|October 13, 2025
Effects of empagliflozin on conventional and exploratory acute and chronic kidney outcomes: an individual participant-level meta-analysisWilliam G Herrington, Zhaojing J Che, Rebecca Sardell, et al.
Eclinicalmedicine|July 21, 2025
Effects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trialJunwen Zhou, Claire Williams, Natalie Staplin, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|November 12, 2024
The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trialParminder K Judge, Katherine R Tuttle, Natalie Staplin, et al.
Clinical Journal of the American Society of Nephrology : CJASN|July 1, 2024
Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trialKaitlin J Mayne, Rebecca J Sardell, Natalie Staplin, et al.
Clinical Journal of the American Society of Nephrology : CJASN|April 3, 2025
Frailty, Multimorbidity, and Polypharmacy: Exploratory Analyses of the Effects of Empagliflozin from the EMPA-KIDNEY TrialKaitlin J Mayne, Rebecca J Sardell, Natalie Staplin, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|November 2, 2025
Effects of Empagliflozin on Urine Biomarkers in EMPA-KIDNEYGreco B Malijan, Rebecca J Sardell, Natalie Staplin, et al.
Journal of the American Society of Nephrology : JASN|December 12, 2023
Effects of Empagliflozin on Fluid Overload, Weight, and Blood Pressure in CKDKaitlin J Mayne, Natalie Staplin, David F Keane, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|December 13, 2025
Effects of Empagliflozin on Kidney and Cardiac Magnetic Resonance Imaging Measures in Patients With CKD: An EMPA-KIDNEY Mechanistic SubstudyDoreen Zhu, Parminder K Judge, Susan T Francis, et al.
Cardiovascular Diabetology|May 7, 2026
CVOT Summit Report 2025: advances along the cardiovascular-kidney-metabolic disease continuumOliver Schnell, Arnav Agarwal, Michel Azizi, et al.
Pageof 11